Evidence map›Paper›PMID 41982216›Full record

ArticleFrontiers in cardiovascular medicine2026

Identification of pathological CD133+ endothelial cells in venous malformations.

Carrie J Shawber, Averill Clapp, Noa Shapiro-Franklin, Shirley Yang, Mason G Harvill, Emma Iaconetti, Michael J Schonning, Andrew I Zeiler, Meghan Perez, Seung Koh and 2 more

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carrie J ShawberDivision of Reproductive Sciences, Department of Ob/Gyn, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Averill Clapp *Division of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Noa Shapiro-Franklin *Division of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Shirley YangDivision of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Mason G HarvillDivision of Reproductive Sciences, Department of Ob/Gyn, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Emma IaconettiDivision of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Michael J SchonningDivision of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Andrew I ZeilerDivision of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Meghan PerezDivision of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Seung KohDivision of Plastic Surgery, Department of Surgery, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Anna AlkelaiDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
June K WuDivision of Reproductive Sciences, Department of Ob/Gyn, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.

Funding

Protein homeostasis dysfunction in LM and VM pathobiology and therapeutic responsesR01HL166726 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Carrie J Shawber, June Kar-ming Wu · 2023 to 2026
$2.5M
NHLBI NIH HHS R01 HL166726
6 · The paper itself

Abstract

Introduction: Venous malformations (VMs) are congenital malformations of the venous system. Histologically, they are composed of dilated vascular channels. Prior studies have demonstrated that CD31 + endothelial cells (ECs) in VMs have pathogenic variants. Recent studies by our group found that the EC progenitor marker, CD133+, was expressed on VM endothelium in patient tissues. We hypothesized that a CD133+ VM endothelial cells contributes to VM pathobiology. Methods: VM cells were isolated from resected venous malformation tissues or fluid using CD133 as a marker. Isolated VM populations were characterized by quantative RT-PCR, fluorescence-activated cell sorting (FACS) and immunofluorescence staining (IF) for the expression of progenitor and mature EC genes/proteins. Cells underwent whole exome sequencing (WES) to probe for genetic variants. AKT and ERK activation status was assessed by Western blot and IF, and cell proliferation determined. Isolated CD133+ cells were xenografted in mice and their ability to recapitulate VM phenotype was assessed by histological analysis, IF and colormetric staining. Results: CD133+ cells isolated from VMs expressed progenitor and mature EC genes and proteins, and we termed them CD133+ VM endothelial cells (CD133+ VMECs). WES revealed CD133+ VMECs had pathogenic variants and variants of uncertain significance in genes reported in VMs, Conclusion: We have identified a novel cell type in VMs, CD133+ VMECs that express EC progenitor proteins, demonstrating incomplete or misdirected differentiation down the EC lineage and are capable of recapitulate the phenotype in a mouse model.

Indexed as

endothelial cellsprogenitorvenous malformationswhole exome sequencingxenograft

Identifiers

PMID41982216
PMCPMC13070831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.